Stock Track | United Therapeutics Soars 5.19% Intraday on Strong Q4 Earnings Beat and Tyvaso Growth

Stock Track

Feb 25

United Therapeutics' stock soared 5.19% during intraday trading on Wednesday, following the release of its fourth-quarter 2025 financial results.

The company reported quarterly earnings of $7.70 per diluted share, which significantly exceeded analyst estimates. Consensus estimates ranged from $6.67 to $7.24, marking a substantial beat. While quarterly revenue of $790.2 million slightly missed some estimates, it still represented a 7.4% increase compared to the same period last year.

The strong earnings performance was driven by continued robust growth of its key product, Tyvaso. Total Tyvaso revenues for Q4 reached $464.3 million, a 12% year-over-year increase, with the Tyvaso DPI formulation showing particularly strong growth of 24%. The company also highlighted a 66% increase in Adcirca net product sales and announced it had entered into accelerated share repurchase agreements to buy back approximately $1.0 billion of its common stock in August 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1158420274"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158420274\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158420274?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158420274","market":"sg","top_or_hot":-1,"title":"Stock Track | United Therapeutics Soars 5.19% Intraday on Strong Q4 Earnings Beat and Tyvaso Growth","media":"Stock Track","content":"<p>United Therapeutics' stock soared 5.19% during intraday trading on Wednesday, following the release of its fourth-quarter 2025 financial results.</p><p>The company reported quarterly earnings of $7.70 per diluted share, which significantly exceeded analyst estimates. Consensus estimates ranged from $6.67 to $7.24, marking a substantial beat. While quarterly revenue of $790.2 million slightly missed some estimates, it still represented a 7.4% increase compared to the same period last year.</p><p>The strong earnings performance was driven by continued robust growth of its key product, Tyvaso. Total Tyvaso revenues for Q4 reached $464.3 million, a 12% year-over-year increase, with the Tyvaso DPI formulation showing particularly strong growth of 24%. The company also highlighted a 66% increase in Adcirca net product sales and announced it had entered into accelerated share repurchase agreements to buy back approximately $1.0 billion of its common stock in August 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | United Therapeutics Soars 5.19% Intraday on Strong Q4 Earnings Beat and Tyvaso Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | United Therapeutics Soars 5.19% Intraday on Strong Q4 Earnings Beat and Tyvaso Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>United Therapeutics' stock soared 5.19% during intraday trading on Wednesday, following the release of its fourth-quarter 2025 financial results.</p><p>The company reported quarterly earnings of $7.70 per diluted share, which significantly exceeded analyst estimates. Consensus estimates ranged from $6.67 to $7.24, marking a substantial beat. While quarterly revenue of $790.2 million slightly missed some estimates, it still represented a 7.4% increase compared to the same period last year.</p><p>The strong earnings performance was driven by continued robust growth of its key product, Tyvaso. Total Tyvaso revenues for Q4 reached $464.3 million, a 12% year-over-year increase, with the Tyvaso DPI formulation showing particularly strong growth of 24%. The company also highlighted a 66% increase in Adcirca net product sales and announced it had entered into accelerated share repurchase agreements to buy back approximately $1.0 billion of its common stock in August 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"","article_id":"1158420274","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158420274","pubTimestamp":1772030955,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"United Therapeutics' stock soared 5.19% during intraday trading on Wednesday, following the release of its fourth-quarter 2025 financial results.The company reported quarterly earnings of $7.70 per...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗"},"translate_title":"股票追踪|United Therapeutics盘中飙升5.19%，因第四季度盈利强劲增长和Tyvaso增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1},"content_text":"United Therapeutics' stock soared 5.19% during intraday trading on Wednesday, following the release of its fourth-quarter 2025 financial results.The company reported quarterly earnings of $7.70 per diluted share, which significantly exceeded analyst estimates. Consensus estimates ranged from $6.67 to $7.24, marking a substantial beat. While quarterly revenue of $790.2 million slightly missed some estimates, it still represented a 7.4% increase compared to the same period last year.The strong earnings performance was driven by continued robust growth of its key product, Tyvaso. Total Tyvaso revenues for Q4 reached $464.3 million, a 12% year-over-year increase, with the Tyvaso DPI formulation showing particularly strong growth of 24%. The company also highlighted a 66% increase in Adcirca net product sales and announced it had entered into accelerated share repurchase agreements to buy back approximately $1.0 billion of its common stock in August 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}